CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC-1295
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Overview
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
Key benefits
- Convenient weekly dosing
- Sustained GH/IGF-1 elevation
- 6-8 day half-life
- Significant body composition changes
Mechanism of action
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Molecular data
- Type
- GHRH analog with DAC
- Half-life
- 6-8 days
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys
Indications
What the research community uses this compound for, with self-reported effectiveness.
Growth Hormone
Body Composition
Anti-Aging
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 1mg | Once weekly | — |
| — | 2mg | Once weekly | — |
| — | 1mg | Twice weekly (Mon/Thu) | — |
| — | 2mg first week, then 1mg | Weekly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Water retention
- Joint pain
- Carpal tunnel symptoms
Contraindications
- Diabetes history
- Cancer history
- Predisposed sleep apnea
Monitoring
- Regular IGF-1 monitoring recommended for long-term use
- Higher incidence of side effects than pulsatile protocols
References
Primary literature and clinical-trial data informing this entry.